{"paperCount": 2, "variants": {"chr17:43093613:G>A": [{"hgvsRna": "NM_007294.3:c.1918C>T|NM_007300.3:c.1918C>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they (c.181T>G (BIC: 300T>G/C61G), c.5266dupC,<<< c.1687C>T>>> (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|Of note,<<< c.1687C>T>>> is also frequent in Slovenia [43] and Sweden (BIC database).|vely (Rappaport, personal communication).  ### Slovenia  In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene <<<(c.1687C>T>>>, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|Another BRCA1 mutation,<<< c.1687C>T>>>, occurs primarily in southern Sweden as well as other European countries (BIC database).|n Sweden, six mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC,<<< c.1687C>T>>>, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|pC     5382insC    \u00a0       Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A     <<< c.1687C>T>>>     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4    \u00a0       c.2676_2679del4     2795del4    \u00a0       Slovenian     c.1687C>T |  c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4    \u00a0       c.2676_2679del4     2795del4    \u00a0       Slovenian    <<< c.1687C>T>>>     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G    \u00a0       c.5266dupC     5382insC    \u00a0       c.181T>A     300T>A    \u00a0       Ital| Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG      c.2475delC     2594delC    \u00a0       c.1082_1092del11     1201del11    \u00a0      <<< c.1687C>T>>>     1806C>T    \u00a0       c.3626delT (Northern)     3745delT    \u00a0       c.1016dupA     1135insA    \u00a0       exon 13 duplication (ins6kbEx13)    \u00a0       N", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "11685,11923,12908,29946,30674,42506,42655,45419", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.1687C>T|NM_007300.3:c.1687C>T", "geneEnds": "", "texts": " c.1687C>T|c.1687C>T", "dbSnpSnippets": "", "mutEnds": "11695,11933,12918,29956,30684,42516,42665,45429", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80356898|rs80356898", "entrezId": "672"}], "chr17:43093171:T>TC,chr17:g.43093172:C>CC": [{"hgvsRna": "NM_007294.3:c.2590dupG|NM_007300.3:c.2590dupG|NM_007299.3:c.2552dupG|NM_007297.3:c.2639dupG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "[91] in a 49 BRCA1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G),<<< c.2359dupG>>> (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132d|BRCA1<<< c.2359dupG>>> and BRCA2 c.516+1G>A have not yet been reported in other populations.  ### The Netherlands (Holland)  Several founder mutations in BRCA1/2 have been identified in Holland [94], where significant regional and cultural differences exist.|   5272-1G>A    \u00a0       Portuguese    \u00a0  \u00a0   c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A     <<< c.2359dupG>>>     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804d", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "20413,20803,43784", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123dupA|c.123dupA|c.123dupA", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.2359dupG|NM_007300.3:c.2359dupG|NM_007299.3:c.2359dupG|NM_007297.3:c.2359dupG", "geneEnds": "", "texts": "c.2359dupG| c.2359dupG", "dbSnpSnippets": "", "mutEnds": "20424,20814,43795", "protId": "", "dbSnpStarts": "", "patType": "dup", "rsIds": "rs397508964|rs397508964|na|na", "entrezId": "672"}], "chr17:g.43067608:C>T": [{"hgvsRna": "NM_007294.3:c.5305G>A|NM_007297.3:c.5354G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": " population, 8.5% of consecutive unselected breast cancer cases, 7.9% of ovarian cancer cases and 40% of male breast cancer cases [6, 146].  The BRCA1<<< c.5074G>A>>> (BIC: 5193G>A) is another founder mutation recently identified in Icelandic population, however it is extremely rare and contributes only to 1% of br", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "33940", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5074G>A|NM_007297.3:c.5074G>A", "geneEnds": "", "texts": "c.5074G>A", "dbSnpSnippets": "", "mutEnds": "33950", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80187739|rs80357283", "entrezId": "672"}], "chr13:g.32371005:AG>-,chr13:32371000:AAG>A": [{"hgvsRna": "NM_000059.3:c.8763_8764delAG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": " of BRCA1/2 mutations to breast cancer predisposition has been reported for populations from the Northern part of the island [67], where founder BRCA2<<< c.8537_8538delAG>>> (BIC: 8765delAG) mutation comprises 28% for BRCA1/2 positive families [68, 69].|, c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T),<<< c.8537_8538delAG>>> (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the French-Canadian population in Quebec [78].|Among these, the most common founder mutations are BRCA1 c.4327C>T and BRCA2<<< c.8537_8538delAG>>> and c.3170_3174del5, which are found in 1.7% of women affected by breast cancer diagnosed before age 41 and in 1.3% of women with ovarian cancer [6].|81T>G     300T>G    \u00a0       c.5266dupC     5382insC    \u00a0       c.181T>A     300T>A    \u00a0       Italian (Tuscany)     c.3228_3229delAG     3347delAG    <<< c.8537_8538delAG>>>  (Sardinia)     8765delAG      c.3285delA     3404delA    \u00a0       c.1380dupA     1499insA    \u00a0       c.5062_5064del3     5181delGTT    \u00a0       Italia", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "14227,16794,17092,42867", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.8537_8538delAG", "geneEnds": "", "texts": " c.8537_8538delAG|c.8537_8538delAG", "dbSnpSnippets": "", "mutEnds": "14244,16811,17109,42884", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359716", "entrezId": "675"}], "chr17:43091904:TA>T,chr17:g.43091905:A>-": [{"hgvsRna": "NM_007294.3:c.3857delT|NM_007300.3:c.3857delT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "Yet another BRCA1 mutation<<< c.3626delT>>> (BIC: 3745delT) apparently originates in northern Sweden and Finland [121].  The 6-kb duplication of BRCA1 exon 13, aslo known as ins6kbEx13 (HGVS: c|The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA),<<< c.3626delT>>> (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|171ins5     c.4258delG     4486delG      c.2475delC     2594delC    \u00a0       c.1082_1092del11     1201del11    \u00a0       c.1687C>T     1806C>T    \u00a0      <<< c.3626delT>>> (Northern)     3745delT    \u00a0       c.1016dupA     1135insA    \u00a0       exon 13 duplication (ins6kbEx13)    \u00a0       Norwegian     c.1556delA     1675de|ins6kbEx13)    \u00a0       Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T     <<< c.3626delT>>>     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     934", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "30072,32638,45452,46189", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT|c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.3626delT|NM_007300.3:c.3626delT", "geneEnds": "", "texts": " c.3626delT|c.3626delT", "dbSnpSnippets": "", "mutEnds": "30083,32649,45463,46200", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357571|rs80357571", "entrezId": "672"}], "chr13:32338201:TG>T,chr13:g.32338202:G>-": [{"hgvsRna": "NM_000059.3:c.4073delG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "1 c.3178G>T (BIC: 3297G>T), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4),<<< c.3847delG>>>T (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|      exon 13 duplication (ins6kbEx13)    \u00a0       Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG    <<< c.3847delG>>>T     4075delGT      c.697delGT     816delGT    \u00a0       c.1016dupA     1135insA    \u00a0       c.3178G>T     3297G>T    \u00a0       c.4745delA     4864delA   ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "31603,45678", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.3847delG", "geneEnds": "", "texts": "c.3847delG| c.3847delG", "dbSnpSnippets": "", "mutEnds": "31614,45689", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs397507691", "entrezId": "675"}], "chr13:32363529:T>G": [{"hgvsRna": "NM_000059.3:c.8553T>G", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "equently.  The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T),<<< c.8327T>G>>> (BIC: 8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+1G>A), c.7480C>T,<<< c.8327T>G>>> in BRCA2 genes.  The mutation spectrum in Eastern part slightly differs from those observed in the Northern and Southern parts of the country [139]. |sh     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT    <<< c.8327T>G>>>     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "32943,33233,46217", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.8327T>G", "geneEnds": "", "texts": "c.8327T>G| c.8327T>G", "dbSnpSnippets": "", "mutEnds": "32953,33243,46227", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs397507977", "entrezId": "675"}], "chr13:g.32394742:AA>-,chr13:32394740:TAA>T": [{"hgvsRna": "NM_000059.3:c.9536_9537delAA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "utations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC: c.6857delAA), c.9026_9030del5 (BIC: 9254-9258del5),<<< c.9310_9311delAA>>> (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79].  Diez et al., [80] have reviewed the frequency of BRCA1 and BRCA2 recurrent mutation|licia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A    <<< c.9310_9311delAA>>>     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A    \u00a0       Portuguese    \u00a0  \u00a0   ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "17916,43512", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.9310_9311delAA", "geneEnds": "", "texts": " c.9310_9311delAA|c.9310_9311delAA", "dbSnpSnippets": "", "mutEnds": "17933,43529", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359756", "entrezId": "675"}], "chr17:43091820:TA>T,chr17:g.43091821:A>-": [{"hgvsRna": "NM_007294.3:c.3941delT|NM_007300.3:c.3941delT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "opean mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and<<< c.3710delT>>> (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111]. The c.2475delC BRCA1 mutation was also |c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4     <<< c.3710delT>>>     3829delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion    \u00a0       Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486de", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "27608,45174", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.3710delT|NM_007300.3:c.3710delT", "geneEnds": "", "texts": "c.3710delT| c.3710delT", "dbSnpSnippets": "", "mutEnds": "27619,45185", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357564|rs80357564", "entrezId": "672"}], "chr17:43047665:C>T": [{"hgvsRna": "NM_007294.3:c.5676G>A|NM_007300.3:c.5676G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and<<< c.5445G>A>>> - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1:<<< c.5445G>A>>>-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  O|)   Total  73        Gene: Mutation  5  6.8      BRCA1: c.2728C>T - p.(Gln910*)  1    Ov (55)  0   BRCA1: c.5407-?_(*1_?)del  1    Br (37)  0   BRCA1:<<< c.5445G>A>>> - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.(Asn2436Lysfs*33)  1    Br (38,45,47,52) & Ov (60, 64)  0   BRCA2: c.9026_9030del - p.(Tyr3009Se|The description of the mutations are in Table \u200bTable4,4, as follows: BRCA1: c.2728C>T - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del,<<< c.5445G>A>>> - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del - p.(Tyr3009Serfs*|  BRCA1:  <<< c.5445G>A>>> - p.(Trp1815*) rs397509284  This mutation is deposited by different laboratories at least 5 times at the LOVD.", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "4898,15111,16945,18635,19549", "docId": "30186769", "varId": "30186769", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5445G>A|NM_007300.3:c.5445G>A", "geneEnds": "", "texts": "c.5445G>A| c.5445G>A", "dbSnpSnippets": "", "mutEnds": "4908,15121,16955,18645,19559", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs397509284|rs397509275", "entrezId": "672"}], "chr17:g.43094834:C>-": [{"hgvsRna": "NM_007294.3:c.928delG|NM_007300.3:c.928delG|NM_007299.3:c.890delG|NM_007298.3:c.715delG|NM_007297.3:c.977delG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "ncer in this region [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG),<<< c.697delG>>>T (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|kbEx13)    \u00a0       Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT     <<< c.697delG>>>T     816delGT    \u00a0       c.1016dupA     1135insA    \u00a0       c.3178G>T     3297G>T    \u00a0       c.4745delA     4864delA    \u00a0       c.2351del7     2470de", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "31085,45709", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.697delG|NM_007300.3:c.697delG|NM_007299.3:c.697delG|NM_007298.3:c.697delG|NM_007297.3:c.697delG", "geneEnds": "", "texts": "c.697delG| c.697delG", "dbSnpSnippets": "", "mutEnds": "31095,45719", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "na|na|na|na|na", "entrezId": "672"}], "chr17:43093844:G>A": [{"hgvsRna": "NM_007294.3:c.1918C>T|NM_007300.3:c.1918C>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they (c.181T>G (BIC: 300T>G/C61G), c.5266dupC,<<< c.1687C>T>>> (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|Of note,<<< c.1687C>T>>> is also frequent in Slovenia [43] and Sweden (BIC database).|vely (Rappaport, personal communication).  ### Slovenia  In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene <<<(c.1687C>T>>>, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|Another BRCA1 mutation,<<< c.1687C>T>>>, occurs primarily in southern Sweden as well as other European countries (BIC database).|n Sweden, six mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC,<<< c.1687C>T>>>, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|pC     5382insC    \u00a0       Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A     <<< c.1687C>T>>>     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4    \u00a0       c.2676_2679del4     2795del4    \u00a0       Slovenian     c.1687C>T |  c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4    \u00a0       c.2676_2679del4     2795del4    \u00a0       Slovenian    <<< c.1687C>T>>>     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G    \u00a0       c.5266dupC     5382insC    \u00a0       c.181T>A     300T>A    \u00a0       Ital| Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG      c.2475delC     2594delC    \u00a0       c.1082_1092del11     1201del11    \u00a0      <<< c.1687C>T>>>     1806C>T    \u00a0       c.3626delT (Northern)     3745delT    \u00a0       c.1016dupA     1135insA    \u00a0       exon 13 duplication (ins6kbEx13)    \u00a0       N", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "11685,11923,12908,29946,30674,42506,42655,45419", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.1687C>T|NM_007300.3:c.1687C>T", "geneEnds": "", "texts": " c.1687C>T|c.1687C>T", "dbSnpSnippets": "", "mutEnds": "11695,11933,12918,29956,30684,42516,42665,45429", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80356898|rs80356898", "entrezId": "672"}], "chr13:g.32338185:A>-": [{"hgvsRna": "NM_000059.3:c.3830delA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC:<<< 3604delA>>>), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|eletion    \u00a0       exon 13 duplication (ins6kbEx13)    \u00a0       Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA    <<< 3604delA>>>     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "32627,46149", "docId": "23199084", "varId": "23199084", "mutPatNames": "6174delT|6174delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.3604delA", "geneEnds": "", "texts": " 3604delA|3604delA", "dbSnpSnippets": "", "mutEnds": "32636,46158", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "na", "entrezId": "675"}], "chr17:43091870:C>A": [{"hgvsRna": "NM_007294.3:c.3892G>T|NM_007300.3:c.3892G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "91] in a 49 BRCA1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG),<<< c.3661G>T>>> (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which ac|nsAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT     <<< c.3661G>T>>>     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "20441,43853", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.3661G>T|NM_007300.3:c.3661G>T", "geneEnds": "", "texts": " c.3661G>T|c.3661G>T", "dbSnpSnippets": "", "mutEnds": "20451,43863", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357310|rs80357310", "entrezId": "672"}], "chr13:32356472:C>T": [{"hgvsRna": "NM_000059.3:c.7706C>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "s also found relatively frequently.  The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other <<<(c.7480C>T>>> (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+1G>A),<<< c.7480C>T>>>, c.8327T>G in BRCA2 genes.  The mutation spectrum in Eastern part slightly differs from those observed in the Northern and Southern parts of the coun|      exon 13 duplication (ins6kbEx13)    \u00a0       Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA    <<< c.7480C>T>>>     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803d", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "32917,33222,46162", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.7480C>T", "geneEnds": "", "texts": " c.7480C>T|c.7480C>T", "dbSnpSnippets": "", "mutEnds": "32927,33232,46172", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80358972", "entrezId": "675"}], "chr17:43099850:TAG>T,chr17:g.43099851:AG>-": [{"hgvsRna": "NM_007294.3:c.701_702delCT|NM_007300.3:c.701_702delCT|NM_007299.3:c.663_664delCT|NM_007298.3:c.488_489delCT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "nt laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A),<<< c.470_471delCT>>> (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC: c.|AA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA     <<< c.470_471delCT>>>     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A    \u00a0       Portuguese    \u00a0  \u00a0   c.156_157insAlu     384insAlu     ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "17702,43548", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.470_471delCT|NM_007300.3:c.470_471delCT|NM_007299.3:c.470_471delCT|NM_007298.3:c.470_471delCT", "geneEnds": "", "texts": " c.470_471delCT|c.470_471delCT", "dbSnpSnippets": "", "mutEnds": "17717,43563", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357887|rs80357887|rs80357887|rs80357887", "entrezId": "672"}], "chr13:32340983:GAA>G,chr13:g.32340984:AA>-": [{"hgvsRna": "NM_000059.3:c.6855_6856delAA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": ": 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4),<<< c.6629_6630delAA>>> (BIC: c.6857delAA), c.9026_9030del5 (BIC: 9254-9258del5), c.9310_9311delAA (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79].  Diez et | 5247G>T    \u00a0       Spanish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G    <<< c.6629_6630delAA>>>     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "17841,43383", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.6629_6630delAA", "geneEnds": "", "texts": " c.6629_6630delAA|c.6629_6630delAA", "dbSnpSnippets": "", "mutEnds": "17858,43400", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359611", "entrezId": "675"}], "chr17:43067648:ATTAG>A,chr17:g.43067649:TTAG>-": [{"hgvsRna": "NM_007294.3:c.5261_5264delCTAA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "5128G>T would appear to be specific to the France, but the analysis of its haplotype is less conclusive and needs further confirmation [6].  The BRCA1<<< c.5030_5033delCTAA>>> (BIC: 5149delCTAA) [76] and c.3839_3843delinsAGGC (BIC: 3958delCTCAGinsAGGC) [77] mutations were reported in at least three independent families from", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "16196", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5030_5033delCTAA", "geneEnds": "", "texts": "c.5030_5033delCTAA", "dbSnpSnippets": "", "mutEnds": "16215", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357862", "entrezId": "672"}], "chr13:g.32339707:C>A": [{"hgvsRna": "NM_000059.3:c.5578C>G|NM_000059.3:c.5578C>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "en) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.<<<(Asn1784Lys>>>fs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|J ethnicity, with two exceptions (Figure \u200b(Figure2):2): proband [B: BRCA1 c.5407-?_(*1_?)del] was half Sephardi, and proband [D: BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3)] was half non-Jewish, although this side was not the side associated with inheritance of the syndrome.  An external file that holds a picture, i|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|Argfs*22)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutation found  1  33.3      BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3)  1    Br (66)  0      Open in a separate window  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer.  Figure \u200bFigure22 depicts the pedigrees for the six families with a non AJ founder mutation.|Table4,4, as follows: BRCA1: c.2728C>T - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del - p.(Tyr3009Serfs*7), rs80359741.  ### Table 4  Families with a non-AJ founder muta|  BRCA2:   c.5351dup - p.<<<(Asn1784Lys>>>fs*3) rs80359508  We have detected this mutation 10 times and it is reported in LOVD at least 49 times (including 7 from our laboratory) (18).|women) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup -<<< p.(Asn1784Lysfs*3>>>); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|r AJ ethnicity, with two exceptions (Figure \u200b(Figure2):2): proband [B: BRCA1 c.5407-?_(*1_?)del] was half Sephardi, and proband [D: BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>)] was half non-Jewish, although this side was not the side associated with inheritance of the syndrome.  An external file that holds a picture, illus|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|982Argfs*22)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutation found  1  33.3      BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>)  1    Br (66)  0      Open in a separate window  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer.  Figure \u200bFigure22 depicts the pedigrees for the six families with a non AJ founder mutation.|e \u200bTable4,4, as follows: BRCA1: c.2728C>T - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del - p.(Tyr3009Serfs*7), rs80359741.  ### Table 4  Families with a non-AJ founder mutation|  BRCA2:   c.5351dup -<<< p.(Asn1784Lysfs*3>>>) rs80359508  We have detected this mutation 10 times and it is reported in LOVD at least 49 times (including 7 from our laboratory) (18).", "geneType": "entrez", "hgvsProt": "NP_000050.2:p.Asn1784Lys", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "prot", "mutStarts": "4949,14370,15161,17877,18699,19885,4946,14367,15158,17874,18696,19882", "docId": "30186769", "varId": "30186769", "mutPatNames": "Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.5352C>G|NM_000059.3:c.5352C>A", "geneEnds": "", "texts": "p.(Asn1784Lysfs*3|Asn1784Lys", "dbSnpSnippets": "", "mutEnds": "4960,14381,15172,17888,18710,19896,4964,14385,15176,17892,18714,19900", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs398122531|rs398122531", "entrezId": "675"}], "chr17:g.43124096:T>G": [{"hgvsRna": "NM_007294.3:c.232A>C|NM_007300.3:c.232A>C|NM_007299.3:c.194A>C|NM_007298.3:c.19A>C|NM_007297.3:c.281A>C", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "BRCA1<<< c.1A>C>>> (BIC: 120A>C) and c.5075-2A>C (BIC: IVS17-2A>C) mutations are also locally frequent.|   \u00a0       c.3178G>T     3297G>T    \u00a0       c.4745delA     4864delA    \u00a0       c.2351del7     2470del7    \u00a0       c.3084del11     3203del11    \u00a0      <<< c.1A>C>>>     120A>C    \u00a0       c.5075-2A>C     IVS17-2A>C    \u00a0       exons 1-13 deletion    \u00a0       exon 13 duplication (ins6kbEx13)    \u00a0       Finnish     c.", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "31696,45919", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.1A>C|NM_007300.3:c.1A>C|NM_007299.3:c.1A>C|NM_007298.3:c.1A>C|NM_007297.3:c.1A>C", "geneEnds": "", "texts": " c.1A>C|c.1A>C", "dbSnpSnippets": "", "mutEnds": "31703,45926", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357287|rs80357287|rs80357287|rs80357287|na", "entrezId": "672"}], "chr17:g.43106457:T>C": [{"hgvsRna": "NM_007294.3:c.442A>G|NM_007300.3:c.442A>G|NM_007299.3:c.404A>G|NM_007298.3:c.229A>G", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "nd geographic distribution.  A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG,<<< c.211A>G>>> (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four m| al., [80] have reviewed the frequency of BRCA1 and BRCA2 recurrent mutations reported in seven geographic areas of Spain.  The founder mutation BRCA1<<< c.211A>G>>>, that leads to aberrant splicing of the transcript, originates from North Western Spain (Galicia) and accounts up to 50% of all mutations in this region [81].|3600del11    \u00a0       c.5128G>T     5247G>T    \u00a0       Spanish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4     <<< c.211A>G>>> (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "17626,18157,43349", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.211A>G|NM_007300.3:c.211A>G|NM_007299.3:c.211A>G|NM_007298.3:c.211A>G", "geneEnds": "", "texts": " c.211A>G|c.211A>G", "dbSnpSnippets": "", "mutEnds": "17635,18166,43358", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357382|rs80357382|rs80357382|rs80357382", "entrezId": "672"}], "chr17:43092353:C>A": [{"hgvsRna": "NM_007294.3:c.3409G>T|NM_007300.3:c.3409G>T|NM_007297.3:c.3458G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "e country, while the fourth is from the south-east [127].  These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1<<< c.3178G>T>>> (BIC: 3297G>T), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT    \u00a0       c.1016dupA     1135insA    \u00a0      <<< c.3178G>T>>>     3297G>T    \u00a0       c.4745delA     4864delA    \u00a0       c.2351del7     2470del7    \u00a0       c.3084del11     3203del11    \u00a0       c.1A>C     120A>C  ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "31454,45779", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.3178G>T|NM_007300.3:c.3178G>T|NM_007297.3:c.3178G>T", "geneEnds": "", "texts": "c.3178G>T| c.3178G>T", "dbSnpSnippets": "", "mutEnds": "31464,45789", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357424|rs80357424|rs80357106", "entrezId": "672"}], "chr17:43071189:AG>A,chr17:g.43071190:G>-": [{"hgvsRna": "NM_007294.3:c.4955delC|NM_007300.3:c.4955delC|NM_007297.3:c.5004delC", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "It was also recurrently found at least four times in Sicilia [70, 71]. Another BRCA1<<< c.4724delC>>> (BIC: 4843delC) mutation could be a possible Sicilian founder mutation, although present evidence is scarce [71, 72, 73].  Using a number of independ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "14872", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.4724delC|NM_007300.3:c.4724delC|NM_007297.3:c.4724delC", "geneEnds": "", "texts": "c.4724delC", "dbSnpSnippets": "", "mutEnds": "14883", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357052|na|na", "entrezId": "672"}], "chr17:43057117:C>T": [{"hgvsRna": "NM_007294.3:c.5443G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "cancer patients, one third carried BRCA2 mutations, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC,<<< c.5212G>A>>> (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for |  9326insA      c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG    \u00a0       Greek     c.5266dupC     5382insC    \u00a0      <<< c.5212G>A>>>     5331G>A    \u00a0       c.5251C>T     5370C>T    \u00a0       c.5467G>A     5586G>A    \u00a0       Cypriot    \u00a0  \u00a0   c.8755delG     8984delG      Danish     c.", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "26385,44838", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5212G>A", "geneEnds": "", "texts": "c.5212G>A| c.5212G>A", "dbSnpSnippets": "", "mutEnds": "26395,44848", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80356937", "entrezId": "672"}], "chr17:43092245:GT>G,chr17:g.43092246:T>-": [{"hgvsRna": "NM_007294.3:c.3516delA|NM_007300.3:c.3516delA|NM_007299.3:c.3478delA|NM_007298.3:c.3303delA|NM_007297.3:c.3565delA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "al founder effect has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations (c.3228_3229delAG (BIC: 3347delAG),<<< c.3285delA>>> (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary |nsC    \u00a0       c.181T>A     300T>A    \u00a0       Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG     <<< c.3285delA>>>     3404delA    \u00a0       c.1380dupA     1499insA    \u00a0       c.5062_5064del3     5181delGTT    \u00a0       Italian (Calabria)     c.4964_4982del19     5083", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "13655,42915", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.3285delA|NM_007300.3:c.3285delA|NM_007299.3:c.3285delA|NM_007298.3:c.3285delA|NM_007297.3:c.3285delA", "geneEnds": "", "texts": " c.3285delA", "dbSnpSnippets": "", "mutEnds": "13666,42926", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs397509051|rs397509051|na|na|rs80356843", "entrezId": "672"}], "chr17:43093055:TG>T,chr17:g.43093056:G>-": [{"hgvsRna": "NM_007294.3:c.2706delC|NM_007300.3:c.2706delC|NM_007299.3:c.2668delC|NM_007298.3:c.2493delC", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "Denmark are a mixture of Scandinavian founder mutations and other European mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were<<< c.2475delC>>> (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, | 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111]. The<<< c.2475delC>>> BRCA1 mutation was also reported in Sweden, Norway and Western Europe (BIC database) and the c.3319G>T BRCA1 mutation was also reported in Norway (ht|Other common BRCA1 mutations in Sweden,<<< c.2475delC>>> and c.1082_1092del11 (BIC: 1201del11), have been detected primarily in families from southern Sweden [118, 119, 120], Denmark and Norway (BIC database).|n the Western Sweden, six mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11,<<< c.2475delC>>>, c.1687C>T, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|G>A     5331G>A    \u00a0       c.5251C>T     5370C>T    \u00a0       c.5467G>A     5586G>A    \u00a0       Cypriot    \u00a0  \u00a0   c.8755delG     8984delG      Danish    <<< c.2475delC>>>     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4|29delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion    \u00a0       Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG     <<< c.2475delC>>>     2594delC    \u00a0       c.1082_1092del11     1201del11    \u00a0       c.1687C>T     1806C>T    \u00a0       c.3626delT (Northern)     3745delT    \u00a0       c.10", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "27539,27733,29758,30662,44995,45342", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.2475delC|NM_007300.3:c.2475delC|NM_007299.3:c.2475delC|NM_007298.3:c.2475delC", "geneEnds": "", "texts": "c.2475delC| c.2475delC", "dbSnpSnippets": "", "mutEnds": "27550,27744,29769,30673,45006,45353", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357970|rs80357970|na|na", "entrezId": "672"}], "chr17:g.43057065:G>GG,chr17:43057062:T>TG": [{"hgvsRna": "NM_007294.3:c.5497dupC", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and<<< c.5266dupC>>> (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC: 6174delT) [31, 32, 33].|these three founder mutations alone is now part of routine clinical practice for Ashkenazi Jewish individuals.  These 3 mutations (BRCA1 c.68_69delAG,<<< c.5266dupC>>> and BRCA2 c.5946delT) account for 98\u201399% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34, 35, 36].|The average risk of breast cancer by the age of 70\u00a0years is similar for carriers of the BRCA1 c.68_69delAG and<<< c.5266dupC>>> mutations (64% and 67% respectively), however is much lower for the c.5946delT mutation (43%).|varian cancer lifetime risk is respectively of 14%, 33% and 20% in carriers, respectively [6, 37, 38].  It is worth noting that BRCA1 c.68_69delAG and<<< c.5266dupC>>> are not found exclusively in Ashkenazi patients.|s with frequencies similar to those in Ashkenazi populations [3], suggesting a common ancient ancestor or two independent mutational events [39].  The<<< c.5266dupC>>> mutation in BRCA1 exon 20 is the second most frequently reported mutation in the BIC database, being very prevalent in Central and Eastern Europe.|A common ancestor for<<< c.5266dupC>>> mutation families reported from Europe, Brazil and North America is evident [46, 56, 57].  ### Austria  In Austria the ratio of BRCA1 mutations to BRCA2 mutations is 2:1 (Rappaport, personal communication).|There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they (c.181T>G (BIC: 300T>G/C61G),<<< c.5266dupC>>>, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|onal communication).  ### Slovenia  In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G,<<< c.5266dupC>>>, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|Eighteen BRCA1 mutations, including the most common<<< c.5266dupC>>>, c.181T>G, c.4065_4068del4 (BIC: 4184del4) and c.2338C>T (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.|The 2 most common BRCA1<<< c.5266dupC>>> and c.181T>G mutations, also prevalent in other populations, accounted for 38% of BRCA1 mutations [4, 99].| (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect [99].  ### Czech Republic  Five mutations (BRCA1: c.181T>G,<<< c.5266dupC>>>, c.3700_3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5 (BIC: 8141del5) and c.8537_8538del2 (BIC: 8765delAG)) represented 52% of all mutations detected in one study population [52].|There is evident strong Slavic founder effect, particularly for two BRCA1 mutations (c.181T>G and<<< c.5266dupC>>>) also regarded as founder mutations in Poland and some other Slavic countries [100].|The single BRCA1<<< c.5266dupC>>> mutation was detected in 51.4% of BRCA1 mutation positive women in one study from Prague area [51].|Three BRCA1 Czech founder mutations (c.181T>G, c.3700_3704del5, and<<< c.5266dupC>>>) account for approximately 9%, 13% and 44% of the BRCA1 mutations identified, respectively [51, 52].  BRCA1 mutations appears to be about 2 times mor|ational spectrum in this population.  ### Hungary  In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations<<< c.5266dupC>>>, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|Breast cancer patients were more likely to carry the<<< c.5266dupC>>> mutation whereas ovarian patients were more likely to carry either the c.68_69delAG or the c.181T>G mutation [103].|enmark  BRCA1 and BRCA2 small scale mutations in Denmark are a mixture of Scandinavian founder mutations and other European mutations, including BRCA1<<< c.5266dupC>>>. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounte|s and other European mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T),<<< c.5266dupC>>> and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111]. The c.2475delC BRCA1 mut|Altogether 7 common BRCA1/2 mutations (excluding<<< c.5266dupC>>> ) accounts for around 35% of carriers [4].  LGRs in BRCA1 and BRCA2 are common in East Denmark and account for 9.2% (15/163) of the disease causing mutations.|The<<< c.5266dupC>>> is also found relatively frequently.  The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three othe|he founder effect [153].  ### Poland  There is strong founder effect in Polish population for BRCA1 gene mutations. In Poland 3 most common mutations <<<(c.5266dupC>>>, c.181T>G and c.4035delA (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations detected and for 86% of all detected mutations in BRCA1/2 genes [40, 100].|The BRCA1<<< c.5266dupC>>>, c.181T>G and c.4035delA accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North- Eastern Poland two common mutations <<<(c.5266dupC>>> and c.181T>G) accounted for more than half (up to 70%) of all BRCA-mutated families and no c.4035delA was identified [156], what is in accordance with other studies [157].|nd its necessary to extend analysis, including LGR, among patients negative for BRCA1/2 founder mutations.  ### Latvia  In Latvia two BRCA1 mutations <<<(c.5266dupC>>> and c.4035delA) made up more than 80% of all mutations BRCA1 identified [50, 158].|The 4154delA mutation is the second most abundant BRCA1 gene mutation after the<<< c.5266dupC>>> in Latvia [50] and is especially common for patients of Baltic (Latvian and Lithuanian) origin.|BRCA1 c.4035delA and<<< c.5266dupC>>> attributes to 86% (53% and 33% respectively) of detected BRCA1 mutations [53, 54, 160].| this mutation in Lithuania.  ### Estonia  Newly published data from Estonia about BRCA1/2 mutations structure showed significant involvement of BRCA1<<< c.5266dupC>>> and to a lesser extent BRCA1 c.4035delA [162], what could be also expected projecting data from adjacent countries.  ### Belarus  Only one small stud|s.  ### Belarus  Only one small study in West Belarus for targeted BRCA1 mutations identified similar spectrum of 3 common mutations as in Poland, and<<< c.5266dupC>>> accounted here for 73% of all BRCA1 mutations [49].  ### Russia  In Russia the most common BRCA1 gene mutation in c.5266dupC, comprising around 90% of all BRCA1 mutations [41, 163, 164, 165, 166, 167].|tations as in Poland, and c.5266dupC accounted here for 73% of all BRCA1 mutations [49].  ### Russia  In Russia the most common BRCA1 gene mutation in<<< c.5266dupC>>>, comprising around 90% of all BRCA1 mutations [41, 163, 164, 165, 166, 167].| BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT     6174delT     <<< c.5266dupC>>>     5382insC    \u00a0       Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c|delAG     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC    \u00a0       Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A     <<< c.5266dupC>>>     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4    \u00a0       c.267|\u00a0       c.2676_2679del4     2795del4    \u00a0       Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G    \u00a0      <<< c.5266dupC>>>     5382insC    \u00a0       c.181T>A     300T>A    \u00a0       Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765|insT    \u00a0       exon 13 deletion (3,8-kb)    \u00a0       exon 22 deletion (510-bp)    \u00a0       German     exon 17 deletion     c.1813dupA     2041insA     <<< c.5266dupC>>>     5382insC     c.4478del4     4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4    \u00a0       c.2338C>T |insA      c.4065_4068del4     4184del4    \u00a0       c.2338C>T     2457C>T    \u00a0       Czech     c.181T>G     300T>G     c.7913_7917del5     8141del5     <<< c.5266dupC>>>     5382insC     c.8537_8538del2     8765delAG      c.3700_3704del5     3819del5    \u00a0       exons 1\u201317 deletion    \u00a0       exons 5\u201314 deletion    \u00a0  |c.8537_8538del2     8765delAG      c.3700_3704del5     3819del5    \u00a0       exons 1\u201317 deletion    \u00a0       exons 5\u201314 deletion    \u00a0       Hungarian    <<< c.5266dupC>>>     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG    \u00a0       Greek     c.5|dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG    \u00a0       Greek    <<< c.5266dupC>>>     5382insC    \u00a0       c.5212G>A     5331G>A    \u00a0       c.5251C>T     5370C>T    \u00a0       c.5467G>A     5586G>A    \u00a0       Cypriot    \u00a0  \u00a0   c.8755de|delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4     <<< c.5266dupC>>>     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion    \u00a0       Swe|4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13)    \u00a0       Irish     c.427G>T     546G>T    \u00a0       Polish    <<< c.5266dupC>>>     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       c.4035delA     4154delA    \u00a0       Latvian     c.4035delA     4154delA    \u00a0       c.5266dupC  |   c.5266dupC     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       c.4035delA     4154delA    \u00a0       Latvian     c.4035delA     4154delA    \u00a0      <<< c.5266dupC>>>     5382insC    \u00a0       Lithuanian     c.4035delA     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Belarusian     c.5266dupC     5382insC  |154delA    \u00a0       Latvian     c.4035delA     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Lithuanian     c.4035delA     4154delA    \u00a0      <<< c.5266dupC>>>     5382insC    \u00a0       Belarusian     c.5266dupC     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       Russian     c.5266dupC     5382insC    \u00a0       Apparently true founder mutations are written in italic.|delA    \u00a0       c.5266dupC     5382insC    \u00a0       Lithuanian     c.4035delA     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Belarusian    <<< c.5266dupC>>>     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       Russian     c.5266dupC     5382insC    \u00a0       Apparently true founder mutations are written in italic.|   4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Belarusian     c.5266dupC     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       Russian    <<< c.5266dupC>>>     5382insC    \u00a0       Apparently true founder mutations are written in italic.", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "9011,9261,9657,9944,10298,11316,11673,12929,23249,23427,23846,24142,24255,24512,25751,26068,27490,27593,28539,32754,36036,36217,36905,37611,37785,38546,40039,40314,40439,42347,42446,42744,44216,44467,44646,44803,45112,46770,46918,47003,47053,47131", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5266dupC", "geneEnds": "", "texts": " c.5266dupC|c.5266dupC", "dbSnpSnippets": "", "mutEnds": "9022,9272,9668,9955,10309,11327,11684,12940,23260,23438,23857,24153,24266,24523,25762,26079,27501,27604,28550,32765,36047,36228,36916,37622,37796,38557,40050,40325,40450,42358,42457,42755,44227,44478,44657,44814,45123,46781,46929,47014,47064,47142", "protId": "", "dbSnpStarts": "", "patType": "dup", "rsIds": "rs397509247", "entrezId": "672"}], "chr13:g.32338215:A>-,chr13:32338208:GA>G": [{"hgvsRna": "NM_000059.3:c.4086delA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21-1G>A) and<<< c.3860delA>>> (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication).  ### Slovenia  In Sloven| Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T    <<< c.3860delA>>>     4088delA      c.3016_3019del4     3135del4    \u00a0       c.2676_2679del4     2795del4    \u00a0       Slovenian     c.1687C>T     1806C>T     c.7806-2A>G", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "12663,42532", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.3860delA", "geneEnds": "", "texts": " c.3860delA|c.3860delA", "dbSnpSnippets": "", "mutEnds": "12674,42543", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359411", "entrezId": "675"}], "chr13:32338612:AG>A,chr13:g.32338613:G>-": [{"hgvsRna": "NM_000059.3:c.4484delG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "5ins6000(dup_ex13) mutation, is quite common in Sweden and is apparently specific to English-speaking and related countries [122].  One BRCA2 mutation<<< c.4258delG>>> (BIC: 4486delG) is found repeatedly in Swedish breast cancer families [120, 123].  In the Western Sweden, six mutations, including the most common BR|_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC, c.1687C>T, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation <<<(c.4258delG>>>) accounted for approximately 75% of all BRCA1/2 mutations [124].|14del4      c.3710delT     3829delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion    \u00a0       Swedish     c.3171_3175dup     3171ins5    <<< c.4258delG>>>     4486delG      c.2475delC     2594delC    \u00a0       c.1082_1092del11     1201del11    \u00a0       c.1687C>T     1806C>T    \u00a0       c.3626delT (Northern)", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "30416,30737,45313", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.4258delG", "geneEnds": "", "texts": " c.4258delG|c.4258delG", "dbSnpSnippets": "", "mutEnds": "30427,30748,45324", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs28897727", "entrezId": "675"}], "chr13:g.32379466:C>-,chr13:32379464:AC>A": [{"hgvsRna": "NM_000059.3:c.9130delC", "comment": "", "isConfirmed": "confirmed", "mutSnippets": " IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT),<<< c.8904delC>>> (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 c.212+3A>G was previously reported as Belgian founder mutation [92, 93], later also found in a few German, Dutch and French families [91].|12+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T    <<< c.8904delC>>>     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delT", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "20551,43879", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.8904delC", "geneEnds": "", "texts": " c.8904delC|c.8904delC", "dbSnpSnippets": "", "mutEnds": "20562,43890", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs41293519", "entrezId": "675"}], "chr17:43104136:C>A": [{"hgvsRna": "NM_007294.3:c.658G>T|NM_007300.3:c.658G>T|NM_007299.3:c.620G>T|NM_007298.3:c.445G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "It is distributed mainly in English- speaking countries or in countries with historical links with Britain.  ### Ireland  A single BRCA1<<< c.427G>T>>> (BIC: 546G>T/E143X) mutation accounts for about 22% of all hereditary breast cancer patients from relatively homogenous Irish population and presumab|lTT      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13)    \u00a0       Irish    <<< c.427G>T>>>     546G>T    \u00a0       Polish     c.5266dupC     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       c.4035delA     4154delA    \u00a0       Latvian     c.4", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "35713,46728", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.427G>T|NM_007300.3:c.427G>T|NM_007299.3:c.427G>T|NM_007298.3:c.427G>T", "geneEnds": "", "texts": "c.427G>T| c.427G>T", "dbSnpSnippets": "", "mutEnds": "35722,46737", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80356991|rs80356991|rs80356991|rs80356991", "entrezId": "672"}], "chr13:32333283:G>GA,chr13:g.32333291:A>AA": [{"hgvsRna": "NM_000059.3:c.2039dupA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "Seven distinct mutations accounted for 28% of BRCA2 mutations, and most frequent<<< c.1813dupA>>> (BIC: 2041insA), c.4478del4 (BIC: 4706del4) and c.9098dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect |elTT      c.1292dupT     1411insT    \u00a0       exon 13 deletion (3,8-kb)    \u00a0       exon 22 deletion (510-bp)    \u00a0       German     exon 17 deletion    <<< c.1813dupA>>>     2041insA      c.5266dupC     5382insC     c.4478del4     4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "23626,44187", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123dupA|c.123dupA", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.1813dupA", "geneEnds": "", "texts": " c.1813dupA|c.1813dupA", "dbSnpSnippets": "", "mutEnds": "23637,44198", "protId": "", "dbSnpStarts": "", "patType": "dup", "rsIds": "rs80359309", "entrezId": "675"}], "chr13:32370434:G>A": [{"hgvsRna": "NM_000059.3:c.8590G>A|NM_000059.3:c.8589G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A<<</W2788X>>>), c.8754+1G>A (BIC: IVS21-1G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, pe", "geneType": "entrez", "hgvsProt": "NP_000050.2:p.Trp2788Stop", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "prot", "mutStarts": "12620", "docId": "23199084", "varId": "23199084", "mutPatNames": "M1775R", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.8364G>A|NM_000059.3:c.8363G>A", "geneEnds": "", "texts": "/W2788X", "dbSnpSnippets": "", "mutEnds": "12627", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs397507981|rs80359080", "entrezId": "675"}], "chr17:43082434:G>A": [{"hgvsRna": "NM_007294.3:c.4558C>T|NM_007300.3:c.4558C>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "In this region 4 BRCA1 gene mutations <<<(c.4327C>T>>> (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC: 3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations|Among these, the most common founder mutations are BRCA1<<< c.4327C>T>>> and BRCA2 c.8537_8538delAG and c.3170_3174del5, which are found in 1.7% of women affected by breast cancer diagnosed before age 41 and in 1.3% of wom|The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT),<<< c.4327C>T>>> (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G     <<< c.4327C>T>>>     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T    \u00a0       c.4096+3A", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "16574,17072,32666,46244", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.4327C>T|NM_007300.3:c.4327C>T", "geneEnds": "", "texts": " c.4327C>T|c.4327C>T", "dbSnpSnippets": "", "mutEnds": "16584,17082,32676,46254", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs41293455|rs41293455", "entrezId": "672"}], "chr13:g.32340728:A>-,chr13:32340722:GA>G": [{"hgvsRna": "NM_000059.3:c.6599delA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "tabase) and the c.3319G>T BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0).  The most common BRCA2 mutations were<<< c.6373delA>>> (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|Two of the recurrent BRCA2 mutations (c.1310_1313del4 and c.6486_6489del4) have also been observed in many other populations, whereas the<<< c.6373delA>>> BRCA2 mutation is less frequent.|.5251C>T     5370C>T    \u00a0       c.5467G>A     5586G>A    \u00a0       Cypriot    \u00a0  \u00a0   c.8755delG     8984delG      Danish     c.2475delC     2594delC    <<< c.6373delA>>>     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710del", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "27972,28319,45023", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.6373delA", "geneEnds": "", "texts": " c.6373delA|c.6373delA", "dbSnpSnippets": "", "mutEnds": "27983,28330,45034", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359578", "entrezId": "675"}], "chr17:43057078:G>A": [{"hgvsRna": "NM_007294.3:c.5482C>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "d BRCA2 mutations, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R),<<< c.5251C>T>>> (BIC: 5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positi|ns are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and<<< c.5251C>T>>> (BIC: 5370C>T).|>G     c.5946delT     6174delT      c.68_69delAG     185delAG    \u00a0       Greek     c.5266dupC     5382insC    \u00a0       c.5212G>A     5331G>A    \u00a0      <<< c.5251C>T>>>     5370C>T    \u00a0       c.5467G>A     5586G>A    \u00a0       Cypriot    \u00a0  \u00a0   c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373d|lT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A     <<< c.5251C>T>>>     5370C>T    \u00a0       c.4096+3A>G     IVS11+3A>G    \u00a0       Iceland    \u00a0  \u00a0   c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "26418,32724,44871,46361", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5251C>T", "geneEnds": "", "texts": "c.5251C>T| c.5251C>T", "dbSnpSnippets": "", "mutEnds": "26428,32734,44881,46371", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357123", "entrezId": "672"}], "chr17:43094569:C>T": [{"hgvsRna": "NM_007294.3:c.1193G>A|NM_007300.3:c.1193G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "In this region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC: 3875delGTCT),<<< c.962G>A>>> (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_85", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "16645", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.962G>A|NM_007300.3:c.962G>A", "geneEnds": "", "texts": "c.962G>A", "dbSnpSnippets": "", "mutEnds": "16654", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357292|rs80357292", "entrezId": "672"}], "chr17:43092848:GTT>G,chr17:g.43092849:TT>-": [{"hgvsRna": "NM_007294.3:c.2912_2913delAA|NM_007300.3:c.2912_2913delAA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "ve in each gene) accounted for almost half of the total mutations detected, and almost one-quarter were accounted by just two founder mutations (BRCA1<<< c.2681_2682delAA>>> (BIC: 2800delAA) and BRCA2 c.6275_6276delTT (BIC: 6503delTT) [149].|The BRCA1<<< c.2681_2682delAA>>>, probably originated from the West-Central Scotland or Ireland [150].|    9345+1G>A      c.5251C>T     5370C>T    \u00a0       c.4096+3A>G     IVS11+3A>G    \u00a0       Iceland    \u00a0  \u00a0   c.771_775del5     999del5      British    <<< c.2681_2682delAA>>> (Scotland)     2800delAA     c.6275_6276delTT (Scotland)     6503delTT      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)    ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "34658,34753,46493", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.2681_2682delAA|NM_007300.3:c.2681_2682delAA", "geneEnds": "", "texts": "c.2681_2682delAA| c.2681_2682delAA", "dbSnpSnippets": "", "mutEnds": "34675,34770,46510", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357971|rs80357971", "entrezId": "672"}], "chr13:32340629:CTT>C,chr13:g.32340630:TT>-": [{"hgvsRna": "NM_000059.3:c.6501_6502delTT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "r mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A),<<< c.6275_6276delTT>>> (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 c.212+3A>G was prev|Together with another Dutch BRCA2 founder mutation<<< c.6275_6276delTT>>> (BIC: 6503delTT), c.5351dupA accounts for 62% of hereditary breast/ovarian families [94, 95].  Slightly outdated (as of year 2002) list of published |f the total mutations detected, and almost one-quarter were accounted by just two founder mutations (BRCA1 c.2681_2682delAA (BIC: 2800delAA) and BRCA2<<< c.6275_6276delTT>>> (BIC: 6503delTT) [149].|BRCA2<<< c.6275_6276delTT>>> has been found elsewhere in the UK as well as in Dutch, Swedish, Danish and Belgian families (BIC database).  In the North-west of England two reccur|uguese    \u00a0  \u00a0   c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG    <<< c.6275_6276delTT>>>     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA  |G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5    <<< c.6275_6276delTT>>>     6503delTT      c.1292dupT     1411insT    \u00a0       exon 13 deletion (3,8-kb)    \u00a0       exon 22 deletion (510-bp)    \u00a0       German     exon 17 de|      c.4096+3A>G     IVS11+3A>G    \u00a0       Iceland    \u00a0  \u00a0   c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)     2800delAA    <<< c.6275_6276delTT>>> (Scotland)     6503delTT      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "20511,21864,34702,34846,43812,44010,46539", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.6275_6276delTT", "geneEnds": "", "texts": "c.6275_6276delTT| c.6275_6276delTT", "dbSnpSnippets": "", "mutEnds": "20528,21881,34719,34863,43829,44027,46556", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs11571658", "entrezId": "675"}], "chr17:g.43094515:T>TT,chr17:43094514:C>CT": [{"hgvsRna": "NM_007294.3:c.1247dupA|NM_007300.3:c.1247dupA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "ix mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC, c.1687C>T,<<< c.1016dupA>>> (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and<<< c.1016dupA>>> make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|The large deletion of BRCA1 exons 1\u201313 is frequently found as well as exon 13 duplication (ins6kb13Ex) (http://www.inherited-cancer.com).  The BRCA1<<< c.1016dupA>>> mutation has also been reported in other countries (Italy, Germany, French-Canada), however allelotyping results indicated an independent origin of this mutation.|5delC     2594delC    \u00a0       c.1082_1092del11     1201del11    \u00a0       c.1687C>T     1806C>T    \u00a0       c.3626delT (Northern)     3745delT    \u00a0      <<< c.1016dupA>>>     1135insA    \u00a0       exon 13 duplication (ins6kbEx13)    \u00a0       Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delA|1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT    \u00a0      <<< c.1016dupA>>>     1135insA    \u00a0       c.3178G>T     3297G>T    \u00a0       c.4745delA     4864delA    \u00a0       c.2351del7     2470del7    \u00a0       c.3084del11     3203de", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "30685,31116,31937,45498,45744", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.1016dupA|NM_007300.3:c.1016dupA", "geneEnds": "", "texts": "c.1016dupA| c.1016dupA", "dbSnpSnippets": "", "mutEnds": "30696,31127,31948,45509,45755", "protId": "", "dbSnpStarts": "", "patType": "dup", "rsIds": "rs80357618|rs80357618", "entrezId": "672"}], "chr17:g.43092803:G>A": [{"hgvsRna": "NM_007294.3:c.2959C>T|NM_007300.3:c.2959C>T|NM_007297.3:c.3008C>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "50 women) harbored one of the 3 mutations (19.7%); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1,<<< c.2728C>T>>> - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|(A) BRCA1<<< c.2728C>T>>> - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(A|2)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5   Unique mutations (NGS)   Total  73        Gene: Mutation  5  6.8      BRCA1:<<< c.2728C>T>>> - p.(Gln910*)  1    Ov (55)  0   BRCA1: c.5407-?_(*1_?)del  1    Br (37)  0   BRCA1: c.5445G>A - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.(|The description of the mutations are in Table \u200bTable4,4, as follows: BRCA1:<<< c.2728C>T>>> - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308de|es with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure \u200bFigure22.  Mutation (HGVS nomenclature)  Description   --- ---   BRCA1:  <<< c.2728C>T>>> - p.(Gln910*) rs397509004  This is a rare mutation reported in ClinVar and we deposited in LOVD (Genomic Variant #0000206572).", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "4850,15045,16850,18577,18981", "docId": "30186769", "varId": "30186769", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.2728C>T|NM_007300.3:c.2728C>T|NM_007297.3:c.2728C>T", "geneEnds": "", "texts": "c.2728C>T| c.2728C>T", "dbSnpSnippets": "", "mutEnds": "4860,15055,16860,18587,18991", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs397509004|rs397509004|rs80356973", "entrezId": "672"}], "chr17:43063903:G>T": [{"hgvsRna": "NM_007294.3:c.5354C>A|NM_007297.3:c.5403C>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": " test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A),<<< c.5123C>A>>> (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039d|3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5     <<< c.5123C>A>>>     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "17676,43486", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5123C>A|NM_007297.3:c.5123C>A", "geneEnds": "", "texts": " c.5123C>A|c.5123C>A", "dbSnpSnippets": "", "mutEnds": "17686,43496", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs28897696|na", "entrezId": "672"}], "chr17:g.43094151:T>TT,chr17:43094150:A>AT": [{"hgvsRna": "NM_007294.3:c.1611dupA|NM_007300.3:c.1611dupA|NM_007297.3:c.1660dupA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "emonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations (c.3228_3229delAG (BIC: 3347delAG), c.3285delA (BIC: 3404delA),<<< c.1380dupA>>> (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ovarian cancer in fam|e fraction (73%) of BRCA1-attributable hereditary breast/ovarian cancer in families originating from Tuscany (Central Italy) area [47, 66].  The BRCA1<<< c.1380dupA>>> mutation was reported in at least 14 families from Tuscany and originated here about 30 generations ago (\u223c750\u00a0years) [65].  In Sardinia, contribution|   \u00a0       Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA    \u00a0      <<< c.1380dupA>>>     1499insA    \u00a0       c.5062_5064del3     5181delGTT    \u00a0       Italian (Calabria)     c.4964_4982del19     5083del19    \u00a0       Italian (North-Eas", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "13683,13916,42950", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123dupA|c.123dupA|c.123dupA", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.1380dupA|NM_007300.3:c.1380dupA|NM_007297.3:c.1380dupA", "geneEnds": "", "texts": "c.1380dupA| c.1380dupA", "dbSnpSnippets": "", "mutEnds": "13694,13927,42961", "protId": "", "dbSnpStarts": "", "patType": "dup", "rsIds": "rs397508863|rs397508863|na", "entrezId": "672"}], "chr17:43093193:G>A": [{"hgvsRna": "NM_007294.3:c.2569C>T|NM_007300.3:c.2569C>T|NM_007298.3:c.2356C>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "Eighteen BRCA1 mutations, including the most common c.5266dupC, c.181T>G, c.4065_4068del4 (BIC: 4184del4) and<<< c.2338C>T>>> (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.| c.5266dupC     5382insC     c.4478del4     4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4    \u00a0      <<< c.2338C>T>>>     2457C>T    \u00a0       Czech     c.181T>G     300T>G     c.7913_7917del5     8141del5      c.5266dupC     5382insC     c.8537_8538del2     8765delAG ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "23307,44366", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.2338C>T|NM_007300.3:c.2338C>T|NM_007298.3:c.2338C>T", "geneEnds": "", "texts": " c.2338C>T|c.2338C>T", "dbSnpSnippets": "", "mutEnds": "23317,44376", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80356945|rs80356945|rs137892861", "entrezId": "672"}], "chr17:43092212:C>A": [{"hgvsRna": "NM_007294.3:c.3550G>T|NM_007300.3:c.3550G>T|NM_007299.3:c.3512G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "ndinavian founder mutations and other European mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC),<<< c.3319G>T>>> (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111|ve families, respectively [109, 110, 111]. The c.2475delC BRCA1 mutation was also reported in Sweden, Norway and Western Europe (BIC database) and the<<< c.3319G>T>>> BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0).  The most common BRCA2 mutations were c.6373delA (BIC: 6601del|   c.5467G>A     5586G>A    \u00a0       Cypriot    \u00a0  \u00a0   c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA     <<< c.3319G>T>>>     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829delT     c.3847_38", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "27567,27837,45052", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.3319G>T|NM_007300.3:c.3319G>T|NM_007299.3:c.3319G>T", "geneEnds": "", "texts": " c.3319G>T|c.3319G>T", "dbSnpSnippets": "", "mutEnds": "27577,27847,45062", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357106|rs80357106|rs111791349", "entrezId": "672"}], "chr17:43063898:C>A": [{"hgvsRna": "NM_007294.3:c.5359G>T|NM_007297.3:c.5408G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The c.3481_3491del11 (BIC: 3600del11) in exon 11 accounts for 37% and the nonsense mutation<<< c.5128G>T>>> (BIC: 5247G>T/Gly1710X) in exon 18 for 15% of all BRCA1/2 mutations in that region (overall 52%) [4, 75].  The haplotype analysis of the families car|The BRCA1 mutation<<< c.5128G>T>>> would appear to be specific to the France, but the analysis of its haplotype is less conclusive and needs further confirmation [6].  The BRCA1 c.5030|   5083del19    \u00a0       Italian (North-East)     c.5062_5064delGTT     5181_5183delGTT    \u00a0       French     c.3481_3491del11     3600del11    \u00a0      <<< c.5128G>T>>>     5247G>T    \u00a0       Spanish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "15615,16043,43219", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5128G>T|NM_007297.3:c.5128G>T", "geneEnds": "", "texts": " c.5128G>T|c.5128G>T", "dbSnpSnippets": "", "mutEnds": "15625,16053,43229", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs397509229|na", "entrezId": "672"}], "chr13:32339699:C>CA,chr13:g.32339706:A>AA": [{"hgvsRna": "NM_000059.3:c.5577dupA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "founder mutations: 3.8-kb deletion of BRCA1 exon 13, also known as c.4186-1643_4357+2020del3835 (BIC: del exon 13del3835/IVS12-1643del3835), and BRCA2<<< c.5351dupA>>> (BIC: 5579insA) were found in families from two different geographical areas, and were prevalent respectively in Catholic (West Braband clustering) and Protestant (South Beveland clustering) families, reflecting religious endogamy [95].|Together with another Dutch BRCA2 founder mutation c.6275_6276delTT (BIC: 6503delTT),<<< c.5351dupA>>> accounts for 62% of hereditary breast/ovarian families [94, 95].  Slightly outdated (as of year 2002) list of published and unpublished BRCA1/2 mutat|8insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA    <<< c.5351dupA>>>     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT      c.1292dupT     1411insT    \u00a0       exon 13 deletion (3,8-kb)    \u00a0  ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "21565,21899,43953", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123dupA|c.123dupA|c.123dupA", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.5351dupA", "geneEnds": "", "texts": " c.5351dupA|c.5351dupA", "dbSnpSnippets": "", "mutEnds": "21576,21910,43964", "protId": "", "dbSnpStarts": "", "patType": "dup", "rsIds": "rs80359509", "entrezId": "675"}], "chr17:43063333:C>T": [{"hgvsRna": "NM_007294.3:c.5424G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "% of consecutive unselected breast cancer cases, 7.9% of ovarian cancer cases and 40% of male breast cancer cases [6, 146].  The BRCA1 c.5074G>A (BIC:<<< 5193G>A>>>) is another founder mutation recently identified in Icelandic population, however it is extremely rare and contributes only to 1% of breast/ovarian c", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "33956", "docId": "23199084", "varId": "23199084", "mutPatNames": "859G>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5193G>A", "geneEnds": "", "texts": "5193G>A", "dbSnpSnippets": "", "mutEnds": "33964", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "na", "entrezId": "672"}], "chr17:43092045:AT>A,chr17:g.43092046:T>-": [{"hgvsRna": "NM_007294.3:c.3716delA|NM_007300.3:c.3716delA|NM_007299.3:c.3678delA|NM_007298.3:c.3503delA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G),<<< c.3485delA>>> (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|   exons 1-13 deletion    \u00a0       exon 13 duplication (ins6kbEx13)    \u00a0       Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5     <<< c.3485delA>>>     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "32610,46134", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.3485delA|NM_007300.3:c.3485delA|NM_007299.3:c.3485delA|NM_007298.3:c.3485delA", "geneEnds": "", "texts": "c.3485delA| c.3485delA", "dbSnpSnippets": "", "mutEnds": "32621,46145", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357509|rs80357509|na|na", "entrezId": "672"}], "chr17:43092301:CCT>C,chr17:g.43092302:CT>-": [{"hgvsRna": "NM_007294.3:c.3459_3460delAG|NM_007300.3:c.3459_3460delAG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "ed families, and significant regional founder effect has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations <<<(c.3228_3229delAG>>> (BIC: 3347delAG), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of B|c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G    \u00a0       c.5266dupC     5382insC    \u00a0       c.181T>A     300T>A    \u00a0       Italian (Tuscany)    <<< c.3228_3229delAG>>>     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA    \u00a0       c.1380dupA     1499insA    \u00a0       c.5062_5064de", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "13620,42832", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.3228_3229delAG|NM_007300.3:c.3228_3229delAG", "geneEnds": "", "texts": "c.3228_3229delAG| c.3228_3229delAG", "dbSnpSnippets": "", "mutEnds": "13637,42849", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357635|rs80357635", "entrezId": "672"}], "chr13:32340440:G>T": [{"hgvsRna": "NM_000059.3:c.6311G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "75delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC:<<< 6085G>T>>>), c.8537_8538delAG (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the French-Canadian population in Quebec [78].", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "16784", "docId": "23199084", "varId": "23199084", "mutPatNames": "859G>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.6085G>T", "geneEnds": "", "texts": "6085G>T", "dbSnpSnippets": "", "mutEnds": "16792", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs397507828", "entrezId": "675"}], "chr17:g.43093065:A>C": [{"hgvsRna": "NM_007294.3:c.2697T>G|NM_007300.3:c.2697T>G|NM_007299.3:c.2659T>G|NM_007297.3:c.2746T>G", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "s Danish founder mutation, comprising 40% (6/15) of all BRCA1/2 families with LGRs [112].  Recently a pathogenic founder BRCA1 mutation c.234T>G (BIC:<<< 2466T>G>>>/Cys39Gly) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "28895", "docId": "23199084", "varId": "23199084", "mutPatNames": "859G>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.2466T>G|NM_007300.3:c.2466T>G|NM_007299.3:c.2466T>G|NM_007297.3:c.2466T>G", "geneEnds": "", "texts": "2466T>G", "dbSnpSnippets": "", "mutEnds": "28903", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "na|na|na|na", "entrezId": "672"}], "chr13:32339924:G>T": [{"hgvsRna": "NM_000059.3:c.5795G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and<<< c.5569G>T>>> (BIC: 5797G>T)).", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "33074", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.5569G>T", "geneEnds": "", "texts": "c.5569G>T", "dbSnpSnippets": "", "mutEnds": "33084", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80358778", "entrezId": "675"}], "chr13:g.32337083:C>T": [{"hgvsRna": "NM_000059.3:c.2954C>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "50 women) harbored one of the 3 mutations (19.7%); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1,<<< c.2728C>T>>> - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|(A) BRCA1<<< c.2728C>T>>> - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(A|2)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5   Unique mutations (NGS)   Total  73        Gene: Mutation  5  6.8      BRCA1:<<< c.2728C>T>>> - p.(Gln910*)  1    Ov (55)  0   BRCA1: c.5407-?_(*1_?)del  1    Br (37)  0   BRCA1: c.5445G>A - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.(|The description of the mutations are in Table \u200bTable4,4, as follows: BRCA1:<<< c.2728C>T>>> - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308de|es with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure \u200bFigure22.  Mutation (HGVS nomenclature)  Description   --- ---   BRCA1:  <<< c.2728C>T>>> - p.(Gln910*) rs397509004  This is a rare mutation reported in ClinVar and we deposited in LOVD (Genomic Variant #0000206572).", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "4850,15045,16850,18577,18981", "docId": "30186769", "varId": "30186769", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.2728C>T", "geneEnds": "", "texts": "c.2728C>T| c.2728C>T", "dbSnpSnippets": "", "mutEnds": "4860,15055,16860,18587,18991", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "na", "entrezId": "675"}], "chr17:g.43124030:CT>-,chr17:43124027:ACT>A": [{"hgvsRna": "NM_007294.3:c.299_300delAG|NM_007300.3:c.299_300delAG|NM_007299.3:c.261_262delAG|NM_007298.3:c.86_87delAG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The most well characterized three founder mutations are two in BRCA1 gene<<< c.68_69delAG>>> (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC: 6174delT) [31, 32, 33].|Screening for these three founder mutations alone is now part of routine clinical practice for Ashkenazi Jewish individuals.  These 3 mutations (BRCA1<<< c.68_69delAG>>>, c.5266dupC and BRCA2 c.5946delT) account for 98\u201399% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34, 35, 36].|The average risk of breast cancer by the age of 70\u00a0years is similar for carriers of the BRCA1<<< c.68_69delAG>>> and c.5266dupC mutations (64% and 67% respectively), however is much lower for the c.5946delT mutation (43%).|ding values for ovarian cancer lifetime risk is respectively of 14%, 33% and 20% in carriers, respectively [6, 37, 38].  It is worth noting that BRCA1<<< c.68_69delAG>>> and c.5266dupC are not found exclusively in Ashkenazi patients.|The<<< c.68_69delAG>>> mutation has been found in patients of Spanish ancestry (i.e.| frequencies and geographic distribution.  A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene <<<(c.68_69delAG>>>, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations |It was also found in French and British families of Spanish origin [82].  The BRCA1<<< c.68_69delAG>>> and BRCA2 c.9026_9030del5 mutations accounted for the 30.4% (7/23) of the BRCA1 mutations and for the 18.5% (5/27) of the BRCA2 positive families respectively and were specific only to the Mediterranean areas.|Indeed, haplotype studies indicated a common origin of<<< c.68_69delAG>>> mutation in Spanish (Sephardic Jewish) and Ashkenazi Jewish populations [83]. Some data indicate an unique origin of reported BRCA2 exon 23 mutation BRCA2 c.9026_9030del5 in Catalan families (North-East Spain) [84].|population.  ### Hungary  In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations c.5266dupC, c.181T>G and<<< c.68_69delAG>>> accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|Breast cancer patients were more likely to carry the c.5266dupC mutation whereas ovarian patients were more likely to carry either the<<< c.68_69delAG>>> or the c.181T>G mutation [103].|By adding two other recurring BRCA1 mutations <<<(c.68_69delAG>>> and c.3700_3704del5), the vast majority (87%) of mutation-positive families will be encompassed.|Other less common mutations found in Western Russia are c.4035delA, c.181T>G, and<<< c.68_69delAG>>>. In Siberian region of Russia there is seen preponderance of individual BRCA2 gene mutations [164].  ### Other countries  In some countries, such as | in European populations  Population     BRCA1 mutation     BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews    <<< c.68_69delAG>>>     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC    \u00a0       Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.52|    c.5062_5064delGTT     5181_5183delGTT    \u00a0       French     c.3481_3491del11     3600del11    \u00a0       c.5128G>T     5247G>T    \u00a0       Spanish    <<< c.68_69delAG>>>     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.511|s 5\u201314 deletion    \u00a0       Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT     6174delT     <<< c.68_69delAG>>>     185delAG    \u00a0       Greek     c.5266dupC     5382insC    \u00a0       c.5212G>A     5331G>A    \u00a0       c.5251C>T     5370C>T    \u00a0       c.5467G>A     ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "8978,9247,9640,9927,10008,17612,18409,18687,25776,26150,37135,40609,42288,43264,44756", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.68_69delAG|NM_007300.3:c.68_69delAG|NM_007299.3:c.68_69delAG|NM_007298.3:c.68_69delAG", "geneEnds": "", "texts": "c.68_69delAG| c.68_69delAG", "dbSnpSnippets": "", "mutEnds": "8991,9260,9653,9940,10021,17625,18422,18700,25789,26163,37148,40622,42301,43277,44769", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs386833395|rs386833395|rs386833395|rs386833395", "entrezId": "672"}], "chr17:43071168:GT>G,chr17:g.43071169:T>-": [{"hgvsRna": "NM_007294.3:c.4976delA|NM_007297.3:c.5025delA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "h is from the south-east [127].  These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC: 3297G>T),<<< c.4745delA>>> (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|   3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT    \u00a0       c.1016dupA     1135insA    \u00a0       c.3178G>T     3297G>T    \u00a0      <<< c.4745delA>>>     4864delA    \u00a0       c.2351del7     2470del7    \u00a0       c.3084del11     3203del11    \u00a0       c.1A>C     120A>C    \u00a0       c.5075-2A>C     IVS17-2A", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "31480,45812", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.4745delA|NM_007297.3:c.4745delA", "geneEnds": "", "texts": "c.4745delA| c.4745delA", "dbSnpSnippets": "", "mutEnds": "31491,45823", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357907|na", "entrezId": "672"}], "chr17:43091495:CT>C,chr17:g.43091496:T>-": [{"hgvsRna": "NM_007294.3:c.4266delA|NM_007300.3:c.4266delA|NM_007297.3:c.4315delA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": " ### Poland  There is strong founder effect in Polish population for BRCA1 gene mutations. In Poland 3 most common mutations (c.5266dupC, c.181T>G and<<< c.4035delA>>> (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations detected and for 86% of all detected mutations in BRCA1/2 genes [40, 100].|The BRCA1 c.5266dupC, c.181T>G and<<< c.4035delA>>> accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North- Eastern Poland two common mutations (c.5266dupC and c.181T>G) accounted for more than half (up to 70%) of all BRCA-mutated families and no<<< c.4035delA>>> was identified [156], what is in accordance with other studies [157].|y to extend analysis, including LGR, among patients negative for BRCA1/2 founder mutations.  ### Latvia  In Latvia two BRCA1 mutations (c.5266dupC and<<< c.4035delA>>>) made up more than 80% of all mutations BRCA1 identified [50, 158].|BRCA1<<< c.4035delA>>> and c.5266dupC attributes to 86% (53% and 33% respectively) of detected BRCA1 mutations [53, 54, 160].|CA1 amplicons by HRM analysis now is the innitial procedure for breast/ovarian cancer patients in our hospital.  The most frequently observed is BRCA1<<< c.4035delA>>> mutation, which is more frequent in families of Baltic (Lithuanian) origin rather than Slavic [53, 54, 161], and was detected in 16.3% (7/43) of unrelated ovarian cancer patients unselected for family history in one study [159].|a  Newly published data from Estonia about BRCA1/2 mutations structure showed significant involvement of BRCA1 c.5266dupC and to a lesser extent BRCA1<<< c.4035delA>>> [162], what could be also expected projecting data from adjacent countries.  ### Belarus  Only one small study in West Belarus for targeted BRCA1 mut|Other less common mutations found in Western Russia are<<< c.4035delA>>>, c.181T>G, and c.68_69delAG. In Siberian region of Russia there is seen preponderance of individual BRCA2 gene mutations [164].  ### Other countries |lication (ins6kbEx13)    \u00a0       Irish     c.427G>T     546G>T    \u00a0       Polish     c.5266dupC     5382insC    \u00a0       c.181T>G     300T>G    \u00a0      <<< c.4035delA>>>     4154delA    \u00a0       Latvian     c.4035delA     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Lithuanian     c.4035delA     4154delA    \u00a0|7G>T     546G>T    \u00a0       Polish     c.5266dupC     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       c.4035delA     4154delA    \u00a0       Latvian    <<< c.4035delA>>>     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Lithuanian     c.4035delA     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Belar| 300T>G    \u00a0       c.4035delA     4154delA    \u00a0       Latvian     c.4035delA     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Lithuanian    <<< c.4035delA>>>     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Belarusian     c.5266dupC     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       Russian     c.5266dupC     5382insC    \u00a0       Apparently true founder mutations are written in italic.", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "36061,36242,37007,37626,38531,39139,40079,40583,46836,46883,46968", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.4035delA|NM_007300.3:c.4035delA|NM_007297.3:c.4035delA", "geneEnds": "", "texts": "c.4035delA| c.4035delA", "dbSnpSnippets": "", "mutEnds": "36072,36253,37018,37637,38542,39150,40090,40594,46847,46894,46979", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357711|rs80357711|na", "entrezId": "672"}], "chr13:32340212:G>T": [{"hgvsRna": "NM_000059.3:c.6083G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "759del4 (BIC: 3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5),<<< c.5857G>T>>> (BIC: 6085G>T), c.8537_8538delAG (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the French-Canadian population in Quebec [78].", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "16768", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.5857G>T", "geneEnds": "", "texts": "c.5857G>T", "dbSnpSnippets": "", "mutEnds": "16778", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80358814", "entrezId": "675"}], "chr17:g.43067617:TAAC>T,chr17:g.43067618:AAC>-": [{"hgvsRna": "NM_007294.3:c.5293_5295delGTT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "[74] showed that previously reported BRCA1<<< c.5062_5064delGTT>>> (BIC: 5181_5183delGTT/1688Val) variant of unknown significance (VUS) actually is a deleterious mutation with high frequency in North-East Italy [74].|The founder<<< c.5062_5064delGTT>>> mutation accounts for 15% (9/61) of families with small BRCA1 mutations.  ### France  In France geographical clustering in North-Eastern part is evident for two recurrent BRCA1 mutations, suggesting a founder effect.|499insA    \u00a0       c.5062_5064del3     5181delGTT    \u00a0       Italian (Calabria)     c.4964_4982del19     5083del19    \u00a0       Italian (North-East)    <<< c.5062_5064delGTT>>>     5181_5183delGTT    \u00a0       French     c.3481_3491del11     3600del11    \u00a0       c.5128G>T     5247G>T    \u00a0       Spanish     c.68_69delAG     185", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "15108,15288,43117", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5062_5064delGTT", "geneEnds": "", "texts": " c.5062_5064delGTT|c.5062_5064delGTT", "dbSnpSnippets": "", "mutEnds": "15126,15306,43135", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80358344", "entrezId": "672"}], "chr13:g.32355085:A>C": [{"hgvsRna": "NM_000059.3:c.7458A>C", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "     Open in a separate window  The following variant of uncertain significance (VUS) was detected in the samples analyzed by NGS: BRCA2:<<< c.7232A>C>>> - p.(Lys2411Thr), rs80358950 (we deposited at LOVD Genomic Variant #0000206714).  ## Discussion  The likelihood that AJ high risk individuals who do ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "21214", "docId": "30186769", "varId": "30186769", "mutPatNames": "c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.7232A>C", "geneEnds": "", "texts": "c.7232A>C", "dbSnpSnippets": "", "mutEnds": "21224", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80358950", "entrezId": "675"}], "chr13:g.32340527:T>A": [{"hgvsRna": "NM_000059.3:c.6172T>A|NM_000059.3:c.6170A>C|NM_000059.3:c.6172T>G", "comment": "", "isConfirmed": "confirmed", "mutSnippets": ", Ov (59, 77)  3 (*)   BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1   BRCA2: c.5946del -p.<<<(Ser1982Arg>>>fs*22)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5   Unique mutations (NGS)   Total  73        Gene: Mutation  5  6.8      BR|found  5  25.0    2   BRCA1: c.68_69del -p.(Glu23Valfs*17)  2    Br (75)  1   BRCA1: c.5266dup -p.(Gln1756Profs*74)  0    0  0   BRCA2: c.5946del - p.<<<(Ser1982Arg>>>fs*22)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutation found  1  33.3      BRCA2: c.5351dup - p.(As|; 2, Ov (59, 77)  3 (*)   BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1   BRCA2: c.5946del <<<-p.(Ser1982Argfs*22>>>)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5   Unique mutations (NGS)   Total  73        Gene: Mutation  5  6.8      BRCA1: |on found  5  25.0    2   BRCA1: c.68_69del -p.(Glu23Valfs*17)  2    Br (75)  1   BRCA1: c.5266dup -p.(Gln1756Profs*74)  0    0  0   BRCA2: c.5946del -<<< p.(Ser1982Argfs*22>>>)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutation found  1  33.3      BRCA2: c.5351dup - p.(Asn1784", "geneType": "entrez", "hgvsProt": "NP_000050.2:p.Ser1982Arg", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "prot", "mutStarts": "16685,17719,16682,17716", "docId": "30186769", "varId": "30186769", "mutPatNames": "Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.5946T>A|NM_000059.3:c.5944A>C|NM_000059.3:c.5946T>G", "geneEnds": "", "texts": "Ser1982Arg|p.(Ser1982Argfs*22", "dbSnpSnippets": "", "mutEnds": "16696,17730,16701,17735", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80359550|na|rs80359550", "entrezId": "675"}], "chr13:g.32339941:G>A": [{"hgvsRna": "NM_000059.3:c.5812G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "## Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC:<<< 5586G>A>>>), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas the rest are unique or low|G     185delAG    \u00a0       Greek     c.5266dupC     5382insC    \u00a0       c.5212G>A     5331G>A    \u00a0       c.5251C>T     5370C>T    \u00a0       c.5467G>A    <<< 5586G>A>>>    \u00a0       Cypriot    \u00a0  \u00a0   c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T  ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "26467,44918", "docId": "23199084", "varId": "23199084", "mutPatNames": "859G>A|859G>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.5586G>A", "geneEnds": "", "texts": "5586G>A| 5586G>A", "dbSnpSnippets": "", "mutEnds": "26475,44926", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "na", "entrezId": "675"}], "chr13:32336283:TG>T,chr13:g.32336284:G>-": [{"hgvsRna": "NM_000059.3:c.2155delG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": " in Dutch, Swedish, Danish and Belgian families (BIC database).  In the North-west of England two reccurent mutations (BRCA1 c.4065_4068del4 and BRCA2<<< c.1929delG>>> (BIC: 2157delG) accounted for 16% of identified BRCA1 mutations in breast/ovarian cancer families and for 20% of BRCA2 positive male breast cancer fa|British     c.2681_2682delAA (Scotland)     2800delAA     c.6275_6276delTT (Scotland)     6503delTT      c.4065_4068del4 (North-West)     4184del4    <<< c.1929delG>>> (North-West)     2157delG      exon 13 duplication (ins6kbEx13)    \u00a0       Irish     c.427G>T     546G>T    \u00a0       Polish     c.5266dupC     5382ins", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "35059,46632", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.1929delG", "geneEnds": "", "texts": " c.1929delG|c.1929delG", "dbSnpSnippets": "", "mutEnds": "35070,46643", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359316", "entrezId": "675"}], "chr17:43063909:C>T": [{"hgvsRna": "NM_007294.3:c.5348G>A|NM_007297.3:c.5397G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "on.  A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G),<<< c.5117G>A>>> (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808|9delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA     <<< c.5117G>A>>>     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "17650,43421", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5117G>A|NM_007297.3:c.5117G>A", "geneEnds": "", "texts": " c.5117G>A|c.5117G>A", "dbSnpSnippets": "", "mutEnds": "17660,43431", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80356860|rs397509246", "entrezId": "672"}], "chr17:g.43047643:C>T": [{"hgvsRna": "NM_007294.3:c.5698G>A|NM_007297.3:c.5747G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "98dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X),<<< c.5467G>A>>> (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas the rest are|   c.68_69delAG     185delAG    \u00a0       Greek     c.5266dupC     5382insC    \u00a0       c.5212G>A     5331G>A    \u00a0       c.5251C>T     5370C>T    \u00a0      <<< c.5467G>A>>>     5586G>A    \u00a0       Cypriot    \u00a0  \u00a0   c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T  ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "26451,44904", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5467G>A|NM_007297.3:c.5467G>A", "geneEnds": "", "texts": "c.5467G>A| c.5467G>A", "dbSnpSnippets": "", "mutEnds": "26461,44914", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357212|na", "entrezId": "672"}], "chr13:g.32337582:TAG>T,chr13:g.32337583:AG>-": [{"hgvsRna": "NM_000059.3:c.3454_3455delAG", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "ed families, and significant regional founder effect has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations <<<(c.3228_3229delAG>>> (BIC: 3347delAG), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of B|c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G    \u00a0       c.5266dupC     5382insC    \u00a0       c.181T>A     300T>A    \u00a0       Italian (Tuscany)    <<< c.3228_3229delAG>>>     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA    \u00a0       c.1380dupA     1499insA    \u00a0       c.5062_5064de", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "13620,42832", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.3228_3229delAG", "geneEnds": "", "texts": "c.3228_3229delAG| c.3228_3229delAG", "dbSnpSnippets": "", "mutEnds": "13637,42849", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359378", "entrezId": "675"}], "chr17:43106487:A>C": [{"hgvsRna": "NM_007294.3:c.412T>G|NM_007300.3:c.412T>G|NM_007299.3:c.374T>G|NM_007298.3:c.199T>G", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they <<<(c.181T>G>>> (BIC: 300T>G/C61G), c.5266dupC, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|port, personal communication).  ### Slovenia  In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene (c.1687C>T,<<< c.181T>G>>>, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|Eighteen BRCA1 mutations, including the most common c.5266dupC,<<< c.181T>G>>>, c.4065_4068del4 (BIC: 4184del4) and c.2338C>T (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.|The 2 most common BRCA1 c.5266dupC and<<< c.181T>G>>> mutations, also prevalent in other populations, accounted for 38% of BRCA1 mutations [4, 99].|c.9098dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect [99].  ### Czech Republic  Five mutations (BRCA1:<<< c.181T>G>>>, c.5266dupC, c.3700_3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5 (BIC: 8141del5) and c.8537_8538del2 (BIC: 8765delAG)) represented 52% of all mutations detected in one study population [52].|There is evident strong Slavic founder effect, particularly for two BRCA1 mutations <<<(c.181T>G>>> and c.5266dupC) also regarded as founder mutations in Poland and some other Slavic countries [100].|Three BRCA1 Czech founder mutations <<<(c.181T>G>>>, c.3700_3704del5, and c.5266dupC) account for approximately 9%, 13% and 44% of the BRCA1 mutations identified, respectively [51, 52].  BRCA1 mutation|trum in this population.  ### Hungary  In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations c.5266dupC,<<< c.181T>G>>> and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|The BRCA1<<< c.181T>G>>> is the most frequent of founder mutations, representing 48% [103].|st cancer patients were more likely to carry the c.5266dupC mutation whereas ovarian patients were more likely to carry either the c.68_69delAG or the<<< c.181T>G>>> mutation [103].|ffect [153].  ### Poland  There is strong founder effect in Polish population for BRCA1 gene mutations. In Poland 3 most common mutations (c.5266dupC,<<< c.181T>G>>> and c.4035delA (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations detected and for 86% of all detected mutations in BRCA1/2 genes [40, 100].|The BRCA1 c.5266dupC,<<< c.181T>G>>> and c.4035delA accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North- Eastern Poland two common mutations (c.5266dupC and<<< c.181T>G>>>) accounted for more than half (up to 70%) of all BRCA-mutated families and no c.4035delA was identified [156], what is in accordance with other studies [157].|The BRCA1<<< c.181T>G>>> is the third recurrent mutation in Latvia, but is not very commonly found.|Two other mutations, BRCA1<<< c.181T>G>>> and recently proved to be pathogenious c.5258G>C (BIC: 5377G>C/R1753T) were also found in more than one family; together with two founder mutations t|Other less common mutations found in Western Russia are c.4035delA,<<< c.181T>G>>>, and c.68_69delAG. In Siberian region of Russia there is seen preponderance of individual BRCA2 gene mutations [164].  ### Other countries  In some c|IC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC    \u00a0       Austrian    <<< c.181T>G>>>     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088de|.3016_3019del4     3135del4    \u00a0       c.2676_2679del4     2795del4    \u00a0       Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A>G     <<< c.181T>G>>>     300T>G    \u00a0       c.5266dupC     5382insC    \u00a0       c.181T>A     300T>A    \u00a0       Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.85| 22 deletion (510-bp)    \u00a0       German     exon 17 deletion     c.1813dupA     2041insA      c.5266dupC     5382insC     c.4478del4     4706del4     <<< c.181T>G>>>     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4    \u00a0       c.2338C>T     2457C>T    \u00a0       Czech     c.181T>G     300T>G   | 4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4    \u00a0       c.2338C>T     2457C>T    \u00a0       Czech    <<< c.181T>G>>>     300T>G     c.7913_7917del5     8141del5      c.5266dupC     5382insC     c.8537_8538del2     8765delAG      c.3700_3704del5     3819del5    \u00a0    |19del5    \u00a0       exons 1\u201317 deletion    \u00a0       exons 5\u201314 deletion    \u00a0       Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA     <<< c.181T>G>>>     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG    \u00a0       Greek     c.5266dupC     5382insC    \u00a0       c.5212G>A     5331G>A  |)     2157delG      exon 13 duplication (ins6kbEx13)    \u00a0       Irish     c.427G>T     546G>T    \u00a0       Polish     c.5266dupC     5382insC    \u00a0      <<< c.181T>G>>>     300T>G    \u00a0       c.4035delA     4154delA    \u00a0       Latvian     c.4035delA     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Lithuanian|insC    \u00a0       Lithuanian     c.4035delA     4154delA    \u00a0       c.5266dupC     5382insC    \u00a0       Belarusian     c.5266dupC     5382insC    \u00a0      <<< c.181T>G>>>     300T>G    \u00a0       Russian     c.5266dupC     5382insC    \u00a0       Apparently true founder mutations are written in italic.", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "11644,12919,23261,23442,23836,24129,24481,25763,25939,26170,36048,36229,36920,38206,38672,40595,42395,42713,44273,44409,44703,46805,47088", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.181T>G|NM_007300.3:c.181T>G|NM_007299.3:c.181T>G|NM_007298.3:c.181T>G", "geneEnds": "", "texts": "c.181T>G| c.181T>G", "dbSnpSnippets": "", "mutEnds": "11653,12928,23270,23451,23845,24138,24490,25772,25948,26179,36057,36238,36929,38215,38681,40604,42404,42722,44282,44418,44712,46814,47097", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs28897672|rs28897672|rs28897672|rs28897672", "entrezId": "672"}], "chr17:g.43106487:A>T": [{"hgvsRna": "NM_007294.3:c.412T>A|NM_007300.3:c.412T>A|NM_007299.3:c.374T>A|NM_007298.3:c.199T>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "4    \u00a0       Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G    \u00a0       c.5266dupC     5382insC    \u00a0      <<< c.181T>A>>>     300T>A    \u00a0       Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404del", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "42779", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.181T>A|NM_007300.3:c.181T>A|NM_007299.3:c.181T>A|NM_007298.3:c.181T>A", "geneEnds": "", "texts": " c.181T>A", "dbSnpSnippets": "", "mutEnds": "42788", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs28897672|rs28897672|rs28897672|rs28897672", "entrezId": "672"}], "chr17:43092844:CTT>C,chr17:g.43092845:TT>-": [{"hgvsRna": "NM_007294.3:c.2916_2917delAA|NM_007300.3:c.2916_2917delAA|NM_007299.3:c.2878_2879delAA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The BRCA1<<< c.2685_2686delAA>>> (BIC: 2804delAA) founder mutation probably originated approximately 32 generations (\u223c200\u00a0years) ago, was also reported few times in Belgium and accounted for 24% of all BRCA1/2 mutations [92].|  IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch    <<< c.2685_2686delAA>>>     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT      c.1292dupT     1411insT    \u00a0       exo", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "21060,43918", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.2685_2686delAA|NM_007300.3:c.2685_2686delAA|NM_007299.3:c.2685_2686delAA", "geneEnds": "", "texts": " c.2685_2686delAA", "dbSnpSnippets": "", "mutEnds": "21077,43935", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357636|rs80357636|na", "entrezId": "672"}], "chr13:32340526:AT>A,chr13:g.32340529:T>-": [{"hgvsRna": "NM_000059.3:c.6400delT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "racterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC:<<< 6174delT>>>) [31, 32, 33].|1 mutation     BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT    <<< 6174delT>>>      c.5266dupC     5382insC    \u00a0       Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     I|  \u00a0       exons 5\u201314 deletion    \u00a0       Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT    <<< 6174delT>>>      c.68_69delAG     185delAG    \u00a0       Greek     c.5266dupC     5382insC    \u00a0       c.5212G>A     5331G>A    \u00a0       c.5251C>T     5370C>T    \u00a0   ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "9072,42333,44742", "docId": "23199084", "varId": "23199084", "mutPatNames": "6174delT|6174delT|6174delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.6174delT", "geneEnds": "", "texts": " 6174delT|6174delT", "dbSnpSnippets": "", "mutEnds": "9081,42342,44751", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "na", "entrezId": "675"}, {"hgvsRna": "NM_000059.3:c.6400delT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "0 individuals is a carrier one of 3 recurrent mutations in BRCA1 [185delAG: c.68_69del (rs386833395) and 5382insC: c.5266dup (rs80357906)], and BRCA2 <<<[6174delT>>>: c.5946del (rs80359550)].", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "7296", "docId": "30186769", "varId": "30186769", "mutPatNames": "6174delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.6174delT", "geneEnds": "", "texts": "[6174delT", "dbSnpSnippets": "", "mutEnds": "7305", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "na", "entrezId": "675"}], "chr13:32338200:CTG>C,chr13:g.32338202:GT>-": [{"hgvsRna": "NM_000059.3:c.4073_4074delGT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "o/id/153250.0).  The most common BRCA2 mutations were c.6373delA (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and<<< c.3847_3848delGT>>> (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].| c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829delT    <<< c.3847_3848delGT>>>     4075delGT      exons 3-16 deletion    \u00a0       Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG      c.2475delC     2594delC   ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "28069,45202", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123_125delAT|c.123_125delAT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.3847_3848delGT", "geneEnds": "", "texts": " c.3847_3848delGT", "dbSnpSnippets": "", "mutEnds": "28086,45219", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359405", "entrezId": "675"}], "chr17:g.43115745:A>C": [{"hgvsRna": "NM_007299.3:c.308T>G|NM_007294.3:c.346T>G|NM_007298.3:c.133T>G|NM_007300.3:c.346T>G", "comment": "", "isConfirmed": "confirmed", "mutSnippets": " founder mutation, comprising 40% (6/15) of all BRCA1/2 families with LGRs [112].  Recently a pathogenic founder BRCA1 mutation c.234T>G (BIC: 2466T>G<<</Cys39Gly>>>) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].", "geneType": "entrez", "hgvsProt": "NP_009230.2:p.Cys39Gly|NP_009225.1:p.Cys39Gly|NP_009229.2:p.Cys39Gly|NP_009231.2:p.Cys39Gly", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "prot", "mutStarts": "28903", "docId": "23199084", "varId": "23199084", "mutPatNames": "Met1775Arg", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007299.3:c.115T>G|NM_007294.3:c.115T>G|NM_007298.3:c.115T>G|NM_007300.3:c.115T>G", "geneEnds": "", "texts": "/Cys39Gly", "dbSnpSnippets": "", "mutEnds": "28912", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80357164|rs80357164|rs80357164|rs80357164", "entrezId": "672"}], "chr13:32340300:GT>G,chr13:g.32340301:T>-": [{"hgvsRna": "NM_000059.3:c.6172delT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2<<< c.5946delT>>> (BIC: 6174delT) [31, 32, 33].|utations alone is now part of routine clinical practice for Ashkenazi Jewish individuals.  These 3 mutations (BRCA1 c.68_69delAG, c.5266dupC and BRCA2<<< c.5946delT>>>) account for 98\u201399% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34, 35, 36].|e age of 70\u00a0years is similar for carriers of the BRCA1 c.68_69delAG and c.5266dupC mutations (64% and 67% respectively), however is much lower for the<<< c.5946delT>>> mutation (43%).|ies, common BRCA1 founder mutations c.5266dupC, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with<<< c.5946delT>>> accounted for 50% of all BRCA2 mutations [42, 103].|lation     BRCA1 mutation     BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG    <<< c.5946delT>>>     6174delT      c.5266dupC     5382insC    \u00a0       Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.87|1\u201317 deletion    \u00a0       exons 5\u201314 deletion    \u00a0       Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G    <<< c.5946delT>>>     6174delT      c.68_69delAG     185delAG    \u00a0       Greek     c.5266dupC     5382insC    \u00a0       c.5212G>A     5331G>A    \u00a0       c.5251C>T     53", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "9055,9282,9736,25866,42318,44727", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.5946delT", "geneEnds": "", "texts": "c.5946delT| c.5946delT", "dbSnpSnippets": "", "mutEnds": "9066,9293,9747,25877,42329,44738", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80359550", "entrezId": "675"}], "chr17:g.43057071:C>G": [{"hgvsRna": "NM_007294.3:c.5489G>C", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "Two other mutations, BRCA1 c.181T>G and recently proved to be pathogenious<<< c.5258G>C>>> (BIC: 5377G>C/R1753T) were also found in more than one family; together with two founder mutations they comprise around 90% of BRCA1 gene mutations and around 85% of all BRCA1/2 mutations identified (Janavi\u010dius, unpublished data).", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "38720", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.5258G>C", "geneEnds": "", "texts": "c.5258G>C", "dbSnpSnippets": "", "mutEnds": "38730", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs397509246", "entrezId": "672"}], "chr17:43094238:T>TA,chr17:g.43094239:A>AA": [{"hgvsRna": "NM_007294.3:c.1523dupT|NM_007300.3:c.1523dupT", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "BRCA1 c.2193del5 (BIC: 2312del5), and<<< c.1292dupT>>> (BIC: 1411insT) mutations were also commonly found [92, 94].  In the south-west of Holland two founder mutations: 3.8-kb deletion of BRCA1 exon 13, a|132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT     <<< c.1292dupT>>>     1411insT    \u00a0       exon 13 deletion (3,8-kb)    \u00a0       exon 22 deletion (510-bp)    \u00a0       German     exon 17 deletion     c.1813dupA     2041", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "21308,44046", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123dupA|c.123dupA", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.1292dupT|NM_007300.3:c.1292dupT", "geneEnds": "", "texts": " c.1292dupT|c.1292dupT", "dbSnpSnippets": "", "mutEnds": "21319,44057", "protId": "", "dbSnpStarts": "", "patType": "dup", "rsIds": "rs80357346|rs80357346", "entrezId": "672"}], "chr17:43093974:CT>C,chr17:g.43093975:T>-": [{"hgvsRna": "NM_007294.3:c.1787delA|NM_007300.3:c.1787delA|NM_007297.3:c.1836delA", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "han 80% of excess number of ovarian cancer after breast cancer in this region [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene <<<(c.1556delA>>> (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|    \u00a0       c.3626delT (Northern)     3745delT    \u00a0       c.1016dupA     1135insA    \u00a0       exon 13 duplication (ins6kbEx13)    \u00a0       Norwegian    <<< c.1556delA>>>     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT    \u00a0       c.1016d", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "31027,45591", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123delT|c.123delT", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.1556delA|NM_007300.3:c.1556delA|NM_007297.3:c.1556delA", "geneEnds": "", "texts": "c.1556delA| c.1556delA", "dbSnpSnippets": "", "mutEnds": "31038,45602", "protId": "", "dbSnpStarts": "", "patType": "del", "rsIds": "rs80357662|rs80357662|na", "entrezId": "672"}], "chr13:32370433:G>A": [{"hgvsRna": "NM_000059.3:c.8589G>A", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "The most prevalent BRCA2 mutations are<<< c.8363G>A>>> (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21-1G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respec| Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC    \u00a0       Austrian     c.181T>G     300T>G    <<< c.8363G>A>>>     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4  ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA2", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "12596,42419", "docId": "23199084", "varId": "23199084", "mutPatNames": "c.123T>A|c.123T>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_000059.3:c.8363G>A", "geneEnds": "", "texts": "c.8363G>A| c.8363G>A", "dbSnpSnippets": "", "mutEnds": "12606,42429", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "rs80359080", "entrezId": "675"}], "chr17:g.43099776:C>A": [{"hgvsRna": "NM_007294.3:c.777G>T|NM_007300.3:c.777G>T|NM_007299.3:c.739G>T|NM_007298.3:c.564G>T", "comment": "", "isConfirmed": "confirmed", "mutSnippets": "t is distributed mainly in English- speaking countries or in countries with historical links with Britain.  ### Ireland  A single BRCA1 c.427G>T (BIC:<<< 546G>T>>>/E143X) mutation accounts for about 22% of all hereditary breast cancer patients from relatively homogenous Irish population and presumably is due to |65_4068del4 (North-West)     4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13)    \u00a0       Irish     c.427G>T    <<< 546G>T>>>    \u00a0       Polish     c.5266dupC     5382insC    \u00a0       c.181T>G     300T>G    \u00a0       c.4035delA     4154delA    \u00a0       Latvian     c.4035delA    ", "geneType": "entrez", "hgvsProt": "", "inDb": "", "geneSymbol": "BRCA1", "end": "", "geneSnippets": "", "geneStarts": "", "start": "", "rsIdsMentioned": "", "seqType": "dna", "mutStarts": "35728,46741", "docId": "23199084", "varId": "23199084", "mutPatNames": "859G>A|859G>A", "offset": "", "dbSnpEnds": "", "chrom": "", "hgvsCoding": "NM_007294.3:c.546G>T|NM_007300.3:c.546G>T|NM_007299.3:c.546G>T|NM_007298.3:c.546G>T", "geneEnds": "", "texts": "546G>T| 546G>T", "dbSnpSnippets": "", "mutEnds": "35735,46748", "protId": "", "dbSnpStarts": "", "patType": "sub", "rsIds": "na|na|na|na", "entrezId": "672"}]}, "stats": {"noarticledata": 0, "novarid": 6, "tried": 400, "duplicates": 111, "notconfirmed": 93, "matched": 79}, "variantCount": 78, "papers": {"30186769": {"vol": "8", "abstract": "In Ashkenazi Jewish (AJ) high risk families 3 mutations [2 in BRCA1 (c. 68_69del and c.5266dup) and 1 inBRCA2 (c.5946del)] account for the majority of high risk breast and ovarian cancer cases in that ethnic group. Few studies with limited number of genotyped individuals have expanded the spectrum of mutations in bothBRCA genes beyond the 3 mutation panel. In this study, 279 high risk individual AJ were counseled at CEMIC (Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas), and were genotyped first for the 3 recurrent mutation panel followed by Next Generation Sequencing (NGS) ofBRCA1 BRCA2 in 76 individuals who tested negative for the first genotyping step. Of 279 probands (259 women), 55 (50 women) harbored one of the 3 mutations (19.7%); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: inBRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); inBRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7). Of 61 mutation carriers the distribution was as follows: 11 cancer free at the time of genotyping, 34 female breast cancer cases with age range 28-72 years (41.6 \u00b1 9.3), 3 male breast cancer cases with age range 59-75 years (65 \u00b1 7.3), 6 breast and ovarian cancer cases with age range 35-60 years (breast 40.4 \u00b1 5.2; ovary 47.8 \u00b1 7.2) and 7 ovarian cancer cases with age range 41-77 years (60.6 \u00b1 13.3). This information proved highly useful for counseling, treatment, and prevention for the patient and the family. In conclusion comprehensiveBRCA1/2 testing in AJ high risk breast ovarian cancer cases adds valuable clinically relevant information in a subset of cases estimated up to 7% and is therefore recommended.", "offset": 1506864983, "authorEmails": "", "chunkId": "0_00000", "year": 2018, "keywords": "", "articleSection": "", "fulltextUrl": "https://www.frontiersin.org/articles/10.3389/fonc.2018.00323/full", "size": "62825", "title": "BRCA1 andBRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina.", "journalUniqueId": "101568867", "source": "", "externalId": "PMID30186769", "articleType": "research-article", "pmid": 30186769, "issue": "", "authorAffiliations": "", "journal": "Frontiers in oncology", "articleId": "5030186769", "origFile": "", "authors": "Solano, Angela R; Liria, Natalia C; Jalil, Fernanda S; Faggionato, Daniela M; Mele, Pablo G; Mampel, Alejandra; Cardoso, Florencia C; Podesta, Ernesto J", "printIssn": "2234-943X", "lang": "eng", "publisher": "Crawl", "doi": "10.3389/fonc.2018.00323", "time": "2018-09-15T00:14:59+0000", "eIssn": "2234-943X", "page": "323", "pmcId": 6113569}, "23199084": {"vol": "1", "abstract": "Detection of mutations in hereditary breast and ovarian cancer-related BRCA1 and BRCA2 genes is an effective method of cancer prevention and early detection. Different ethnic and geographical regions have different BRCA1 and BRCA2 mutation spectrum and prevalence. Along with the emerging targeted therapy, demand and uptake for rapid BRCA1/2 mutations testing will increase in a near future. However, current patients selection and genetic testing strategies in most countries impose significant lag in this practice. The knowledge of the genetic structure of particular populations is important for the developing of effective screening protocol and may provide more efficient approach for the individualization of genetic testing. Elucidating of founder effect in BRCA1/2 genes can have an impact on the management of hereditary cancer families on a national and international healthcare system level, making genetic testing more affordable and cost-effective. The purpose of this review is to summarize current evidence about the BRCA1/2 founder mutations diversity in European populations.", "offset": 78, "authorEmails": "", "chunkId": "0_00000", "year": 2010, "keywords": "", "articleSection": "", "fulltextUrl": "", "size": "126825", "title": "Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.", "journalUniqueId": "101517307", "source": "", "externalId": "PMID23199084", "articleType": "research-article", "pmid": 23199084, "issue": "3", "authorAffiliations": "", "journal": "The EPMA journal", "articleId": "5023199084", "origFile": "", "authors": "Janavi\u010dius, Ram\u016bnas", "printIssn": "1878-5077", "lang": "eng", "publisher": "Crawl", "doi": "10.1007/s13167-010-0037-y", "time": "2018-09-15T00:13:31+0000", "eIssn": "1878-5077", "page": "397", "pmcId": 3405339}}}